From Our Partners
Sunday, June 26, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

BioFire Awarded NGDS Increment 1 Contract from DoD

by Global Biodefense Staff
March 27, 2013

BioFire Diagnostics, Inc. this week announced that it has signed a competitive prototyping contract with the Department of the Army for Increment 1 of the Next Generation Diagnostics System (NGDS) Program.

NGDS is being developed by the Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD), Chemical Biological Medical Systems Biosurveillance (CBMS-BSV) to provide an FDA-cleared diagnostic system for the analysis of clinical and environmental biological warfare agent samples. The system will provide military healthcare providers with timely and accurate information to guide individual patient treatment as well as provide battlefield commanders with biological threat information for situational awareness to support force protection.

For Increment 1, BioFire will develop a panel utilizing their proprietary FilmArray Stystem that will be optimized to detect biothreat agents in blood or environmental samples. The FilmArray System will be evaluated during the Competitive Prototyping Phase and if selected, BioFire will receive a final contract to be awarded later in the year for further system development and obtaining FDA clearance for the panel.

“BioFire has a history of successful developmental efforts with the United States Department of Defense, most notably with the JBAIDS program, and we are excited for this opportunity to demonstrate the capabilities of the FilmArray,” stated Kirk Ririe, Chief Executive Officer of BioFire Diagnostics.

From Our Partners
Tags: AwardsJPEO-CBRNDPOC Diagnostics

Related Posts

Influenza Research
Biodetection

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
NIH to Further Invest in Point-of-Care Technologies Research Network
Biodetection

NIH to Further Invest in Point-of-Care Technologies Research Network

May 10, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC